Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 3
2023 1
2024 6
2025 4
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Current and future immunotherapy for breast cancer.
Heater NK, Warrior S, Lu J. Heater NK, et al. J Hematol Oncol. 2024 Dec 25;17(1):131. doi: 10.1186/s13045-024-01649-z. J Hematol Oncol. 2024. PMID: 39722028 Free PMC article. Review.
Substantial therapeutic advancement has been made in the field of immunotherapy in breast cancer. The immune checkpoint inhibitor pembrolizumab in combination with chemotherapy received FDA approval for both PD-L1 positive metastatic and early-stage triple-negati …
Substantial therapeutic advancement has been made in the field of immunotherapy in breast cancer. The immune checkpoint inhibitor pembrol …
TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy.
Bardia A, Pusztai L, Albain K, Ciruelos EM, Im SA, Hershman D, Kalinsky K, Isaacs C, Loirat D, Testa L, Tokunaga E, Wu J, Dry H, Barlow W, Kozarski R, Maxwell M, Harbeck N, Sharma P. Bardia A, et al. Ther Adv Med Oncol. 2024 Apr 29;16:17588359241248336. doi: 10.1177/17588359241248336. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38686016 Free PMC article.
BACKGROUND: Despite advances in the treatment of early triple-negative breast cancer (TNBC), patients with residual invasive disease after neoadjuvant therapy have a high risk of disease recurrence and worse survival outcomes than those who have …
BACKGROUND: Despite advances in the treatment of early triple-negative breast cancer (TNBC), patients wit …
OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab ( capecitabine) for residual triple-negative breast cancer.
Tolaney SM, DeMichele A, Takano T, Rugo HS, Perou C, Lynce F, Parsons HA, Santa-Maria CA, Rocque GB, Yao W, Sun SW, Mocci S, Partridge AH, Carey LA. Tolaney SM, et al. Future Oncol. 2024;20(31):2343-2355. doi: 10.1080/14796694.2024.2357534. Epub 2024 Jun 26. Future Oncol. 2024. PMID: 38922307 Free PMC article.
Patients with early-stage triple-negative breast cancer (TNBC) with residual invasive disease after neoadjuvant therapy have a high risk of recurrence even with neoadjuvant and adjuvant treatment with pembrolizumab. Sacituzumab …
Patients with early-stage triple-negative breast cancer (TNBC) with residual invasive disease after neoad …
TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2- breast cancer.
McArthur HL, Tolaney SM, Dent R, Schmid P, Asselah J, Liu Q, Meisel JL, Niikura N, Park YH, Werutsky G, Bianchini G, Andersen JC, Kozarski R, Rokutanda N, Pistilli B, Loibl S. McArthur HL, et al. Ther Adv Med Oncol. 2025 Feb 5;17:17588359251316176. doi: 10.1177/17588359251316176. eCollection 2025. Ther Adv Med Oncol. 2025. PMID: 39917260 Free PMC article.
BACKGROUND: Despite treatment advances for patients with early-stage triple-negative breast cancer (TNBC) and hormone receptor (HR)-low/human epidermal growth factor receptor 2-negative (HER2-) breast cancer, treatments that improve clinical out …
BACKGROUND: Despite treatment advances for patients with early-stage triple-negative breast cancer (TNBC) …
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer.
Schmid P, Oliveira M, O'Shaughnessy J, Cristofanilli M, Graff SL, Im SA, Loi S, Saji S, Wang S, Cescon DW, Hovey T, Nawrot A, Tse K, Vukovic P, Curigliano G. Schmid P, et al. Ther Adv Med Oncol. 2025 Apr 17;17:17588359251327992. doi: 10.1177/17588359251327992. eCollection 2025. Ther Adv Med Oncol. 2025. PMID: 40297626 Free PMC article.
BACKGROUND: Standard of care (SoC) for patients with advanced triple-negative breast cancer (TNBC) whose tumors express PD-L1 (combined positive score 10) is chemotherapy plus anti-PD-(L)1 inhibitors; however, prognosis and survival for most p …
BACKGROUND: Standard of care (SoC) for patients with advanced triple-negative breast cancer (TNBC) whose …
Targeted Treatment of Metastatic Triple-Negative Breast Cancer: A Systematic Review.
Hammershøi Madsen AM, Løvendahl Eefsen RH, Nielsen D, Kümler I. Hammershøi Madsen AM, et al. Breast J. 2024 Jul 11;2024:9083055. doi: 10.1155/2024/9083055. eCollection 2024. Breast J. 2024. PMID: 39742383 Free PMC article.
INTRODUCTION: Triple-negative breast cancer (TNBC) is a subgroup of breast cancer characterized by the absence of estrogen and the human epidermal 2 receptor and also a lack of targeted therapy options. ...CONCLUSION: In most of the studies incl …
INTRODUCTION: Triple-negative breast cancer (TNBC) is a subgroup of breast cancer characterized by the ab …
Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer.
Cipriano É, Mesquita A. Cipriano É, et al. Breast Cancer (Auckl). 2021 Mar 22;15:11782234211002491. doi: 10.1177/11782234211002491. eCollection 2021. Breast Cancer (Auckl). 2021. PMID: 33814914 Free PMC article. Review.
Metastatic triple-negative breast cancer (TNBC) is a heterogeneous disease with a poor prognosis and currently with few treatment options. ...Some targeted drugs were recently approved for these patients: two poly(ADP-ribose) polymerase inhibito …
Metastatic triple-negative breast cancer (TNBC) is a heterogeneous disease with a poor prognosis and curr …
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer.
Bartsch R. Bartsch R. Memo. 2021;14(3):247-251. doi: 10.1007/s12254-021-00722-4. Epub 2021 Jun 29. Memo. 2021. PMID: 34221179 Free PMC article. Review.
Despite these circumstances, clinically relevant data were presented, and this short review focuses on developments in the fields of triple-negative breast cancer (TNBC) and metastatic HER2-positive breast cancer. A quality-of-life (QoL) analysi …
Despite these circumstances, clinically relevant data were presented, and this short review focuses on developments in the fields of trip …
Synergistic approach to combating triple-negative breast cancer: DDR1-targeted antibody-drug conjugate combined with pembrolizumab.
Zhou S, Li W, Zhao D, Zhang Q, Liu H, Jin T, Pan Y. Zhou S, et al. J Pharm Anal. 2025 May;15(5):101100. doi: 10.1016/j.jpha.2024.101100. Epub 2024 Sep 13. J Pharm Anal. 2025. PMID: 40521369 Free PMC article.
Discoidin domain receptor 1 (DDR1) is overexpressed in various tumors, such as triple-negative breast cancer (TNBC), and is rarely expressed in normal tissues. These characteristics make DDR1 a preferable target candidate for the construction of …
Discoidin domain receptor 1 (DDR1) is overexpressed in various tumors, such as triple-negative breast cancer ( …
[Triple negative breast cancer: Current status and perspectives].
Le Du F, Moati E, Vaflard P, Bailleux C, Pierga JY, Dieras V. Le Du F, et al. Bull Cancer. 2025 Jan;112(1):82-99. doi: 10.1016/j.bulcan.2024.09.002. Epub 2024 Nov 6. Bull Cancer. 2025. PMID: 39510910 Review. French.
Triple negative breast cancer (TNBC) is defined by the absence of expression of estrogen and progesterone receptors, as well as the absence of overexpression of HER2. ...Furthermore, immunotherapy, particularly pembrolizumab, has shown si …
Triple negative breast cancer (TNBC) is defined by the absence of expression of estrogen and progesterone …
14 results